RE:RE:market has over reacted according to this article"Number three and in recognition that we can’t cut our way to growth, we recently made significant enhancements to our sales and marketing strategies." cc transcript Q32020
At this point, I'm hoping for flat results in Q4.
For sure this is undervalued in terms of assets (Facilities in CA and AUS, GMP certs, Contracts with big pharma, cash position) but the reality is, revenues aren't following, so it is understandable.
It boils down to what has been oversaid on this forum, they've got to show the money, and they are not doing that for now. And with last Q results, investors have reason to doubt it LABS can drive sales up.